What is EyePromise?
EyePromise offers a comprehensive range of scientifically validated eye vitamins designed to enhance both ocular and overall health. Their product portfolio caters to a diverse clientele, including individuals seeking solutions for age-related eye conditions, those experiencing occasional dry eye, and athletes aiming for performance enhancement through nutritional support. The company emphasizes its commitment to quality and efficacy by collaborating closely with eye care professionals and securing endorsements from professional athletes, positioning itself as a trusted provider of vision and wellness nutritional supplements.
How much funding has EyePromise raised?
EyePromise has raised a total of $3.4M across 2 funding rounds:
Private Equity
$3M
Debt
$350K
Private Equity (2014): $3M with participation from DSM Venturing
Debt (2020): $350K led by PPP
Key Investors in EyePromise
DSM Venturing
DSM Venturing is the corporate venture capital arm of Royal DSM, a global science-based company active in Nutrition, Health, and Sustainable Living. They typically invest in innovative companies that align with DSM's strategic focus areas.
PPP
Public-Private Partnership
What's next for EyePromise?
With the recent major strategic investment, EyePromise is poised to further expand its market reach and product development initiatives. This capital infusion is expected to bolster its efforts in scientific research, product innovation, and market penetration, particularly within the enterprise-level healthcare and professional sports sectors. The company's focus on evidence-based nutritional solutions for eye health suggests a strategic direction towards solidifying its position as a leader in preventative eye care and performance-enhancing supplements.
See full EyePromise company page
